Selective Targeting of Cancer Cells using Personalized Nanomedicine

Crossmark: check for updates

Authors

  • Anuradha Gupta Institute of Nano Science and Technology (INST), Habitat Centre, Phase X, Mohali-160062, Punjab, India
  • Anas Ahmad Institute of Nano Science and Technology (INST), Habitat Centre, Phase X, Mohali-160062, Punjab, India
  • Aqib Iqbal Dar Institute of Nano Science and Technology (INST), Habitat Centre, Phase X, Mohali-160062, Punjab, India
  • Aashish Bhatt Institute of Nano Science and Technology (INST), Habitat Centre, Phase X, Mohali-160062, Punjab, India
  • Rehan Khan Institute of Nano Science and Technology (INST), Habitat Centre, Phase X, Mohali-160062, Punjab, India

DOI:

https://doi.org/10.17140/TFMOJ-1-e005

Keywords:

Cancer, Cancer Cell, Nanomedicine, genetic

Abstract

Cancer is mostly caused by genetic alteration in either of gain of function and/or loss of function in response to mutagens, ionizing radiations etc. Synthetic lethality raised as an exciting new avenue to kill cancer cells by identifying potential druggable targets. Synthetic lethality define as a lethal interaction between two separate viable mutations when present together within a cell results in cell death, while mutation is only in either of the genes alone, cell remains viable.

References

van Pel DM, Barrett IJ, Shimizu Y, et al. An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet. 2013; 9(1): e1003254. doi: 10.1371/journal. pgen.1003254

Bakhoum SF, Compton DA. Chromosomal instability and cancer: A complex relationship with therapeutic potential. J Clin Invest. 2012; 122(4): 1138-1143. doi: 10.1172/JCI59954

Ansari M, Krajinovic M. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in re-sponses to chemotherapy. Curr Opin Pediatr. 2007; 19(1): 15-22. doi: 10.1097/MOP.0b013e3280140613

Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics: A bridge to individualized cancer therapy. Pharmacogenomics. 2013; 14(3): 315-324. doi: 10.2217/pgs.12.213

Cho S-H, Jeon J, Kim SI. Personalized medicine in breast cancer: A systematic review. J Breast Cancer. 2012; 15(3): 265-272. doi: 10.4048/jbc.2012.15.3.265

Minko T, Rodriguez-Rodriguez L, Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev. 2013; 65(13): 1880-1895. doi: 10.1016/j.addr.2013.09.017

Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resis-tance. Adv Drug Deliv Rev. 2013; 65(13): 1866-1879. doi: 10.1016/j.addr.2013.09.019

Pathak HB, Zhou Y, Sethi G, et al. A synthetic lethality screen using a focused siRNA library to identify sensitizers to dasatinib therapy for the treatment of epithelial ovarian cancer. PLoS One. 2015; 10(12): e0144126. doi: 10.1371/journal.pone.0144126

Sun T-M, Du JZ, Yao YD, et al. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes syner-gistic tumor suppression. ACS Nano. 2011; 5(2): 1483-1494. doi: 10.1021/nn103349h Toxicol Forensic Med Open J Page e13

Downloads

Published

2016-08-24

How to Cite

Anuradha Gupta, Anas Ahmad, Aqib Iqbal Dar, Aashish Bhatt, & Rehan Khan. (2016). Selective Targeting of Cancer Cells using Personalized Nanomedicine. Toxicology and Forensic Medicine, 1(1), e12-e13. https://doi.org/10.17140/TFMOJ-1-e005

Issue

Vol. 1 No. 1 (2016): Volume 1 Issue 1 2016

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Toxicology and Forensic Medicine (TFM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.